Human CD27/TNFRSF7 Antibody Summary
Accession # P26842
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
CD27/TNFRSF7 Inhibition of CD27 Ligand/TNFSF7-dependent Cell Proliferation and Neutralization by Human CD27/TNFRSF7 Antibody. In the presence of sub-optimal amounts of Mouse CD3 epsilon Monoclonal Antibody (Catalog # MAB484) and Recombinant Mouse CD27 Ligand (10 µg/mL, Catalog # 783-CL), Recombinant Human CD27 Fc Chimera (Catalog # 382-CD) inhibits proliferation in mouse splenic T cells in a dose-dependent manner (orange line). Under these conditions, inhibition of proliferation elicited by Recombinant Human CD27 Fc Chimera (3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CD27 Monoclonal Antibody (Catalog # MAB382). The ND50 is typically 0.2‑0.4 µg/mL.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Human CD27 is a lymphocyte-specific member of the TNF receptor superfamily. CD27 is expressed on a subset of human thymocytes and on the majority of mature T cells. CD27 expression is up-regulated after TCR stimulation. Within the CD4+ compartment, it is preferentially expressed on CD45RA+ cells. In contrast, it is preferentially expressed on CD45RO+ cells in the CD8+ compartment. CD27 also appears to be a potential marker for memory B cells. It exists as both a disulfide‑linked dimer on the cell surface and as a soluble protein found in serum. Human CD27 is a 260 amino acid (aa) protein with a 20 aa signal, a 173 aa extracellular domain, a 20 aa transmembrane domain, and a 47 aa cytoplasmic domain. The ligand for CD27 is CD70. CD70 is expressed on thymic stromal cells and a small subset of activated T cells. Additionally a subset of activated B cells express CD70. The CD27/CD70 interaction appears to be a weak costimulatory pathway involved in T cell and B cell immune response. CD27/CD70 interactions may be more involved in controlling the expansion phase of an immune response. This would be in contrast to B7/CD28 interactions, which are important for the activation phase of immune responses.
- Camerini, D. et al. (1991) J. Immunol. 147:3165.
- Loenen, W.A. et al. (1992) J. Immunol. 149:3937.
- Lens, S.M.A. et al. (1998) Sem. Immunol. 10:491.
Citation for Human CD27/TNFRSF7 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
IL-7 decreases IL-7 receptor alpha (CD127) expression and induces the shedding of CD127 by human CD8+ T cells.
Authors: Vranjkovic A, Crawley AM, Gee K, Kumar A, Angel JB
Int. Immunol., 2007;19(12):1329-39.
Sample Types: Whole Cells
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CD27/TNFRSF7 Antibody
There are currently no reviews for this product. Be the first to review Human CD27/TNFRSF7 Antibody and earn rewards!
Have you used Human CD27/TNFRSF7 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image